𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics

✍ Scribed by B. A. Conley; Merrill J. Egorin; Rajeshwari Sridhara; Rebecca Finley; Ramzi Hemady; Suhlan Wu; Nancy S. Tait; David A. Van Echo; David A. Van Echo

Publisher
Springer
Year
1997
Tongue
English
Weight
200 KB
Volume
39
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I trial of topically applied tra
A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy
✍ Sheldon A. Weiner; Earl A. Surwit; Vivian E. Graham; Frank L. Meyskens πŸ“‚ Article πŸ“… 1986 πŸ› Springer US 🌐 English βš– 260 KB

Forty-two patients were entered into a phase I trial to evaluate the vitamin A derivative, trans-retinoic acid, in cervical intraepithelial neoplasia. Treatment consisted of four consecutive 24-h applications of retinoids via an inert collagen sponge in a cervical cap. Patients were followed for res

Clinical trial of valproic acid and all-
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
✍ Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; K πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 275 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodyspl

Phase I trial of interferon Ξ±2b and lipo
Phase I trial of interferon Ξ±2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma
✍ Jonathan S. Goldberg; Manuel Vargas; Alyssa S. Rosmarin; Matthew I. Milowsky; Ni πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 317 KB

## Abstract ## BACKGROUND Studies suggest that retinoic acid (RA) can augment the antitumor effects of interferon‐based therapy in patients with advanced renal cell carcinoma (RC); however, this benefit has not been achieved convincingly using oral formulations of 13‐cis RA and all‐__trans__ RA. L